1. Scrip

Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy

 
• By Sukaina Virji

Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.

Multiple Sclerosis

Roche's is embarking upon a brave pricing strategy for its new multiple sclerosis drug Ocrevus (ocrelizumab) now that it has finally been licensed by the US FDA, following a slight technical hitch over manufacturing. The drug has been approved to treat both relapsing-remitting MS (RRMS) patients and the underserved primary progressive MS (PPMS) population and has been priced competitively.

The wholesale acquisition cost (WAC) has been set at $65,000, a "25% discount to [Pfizer Inc./Merck KGAA's] Rebif [interferon...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers